ClinicalTrials.gg
CompletedNCT00478231Updated Sep 9, 2011Results posted

Multicenter, Safety Study Of Maraviroc

A Phase 3 interventional study of Maraviroc in Acquired Immunodeficiency Syndrome and HIV Infection, sponsored by ViiV Healthcare. Completed at 16 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-09.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
209
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Maraviroc · Acquired Immunodeficiency Syndrome.

Enrollment
6th of 29
209 · median 31
Started
2007
the only one that year
Phase 3
6 of 29
none open now
Registered
2nd of 29
by date
Lead sponsor
11 of 29
ViiV Healthcare

Among the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 3, and was the 2nd registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

2 of the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome, or all of them as a file.
02

Study summary

To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.

03

Conditions studied

  • Acquired Immunodeficiency Syndrome
  • HIV Infection

Keywords

  • Multicenter
  • Open Label
  • Non-Comparative Safety Study Of Maraviroc
  • Treatment Experienced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with limited or no approved treatment options available to them due to resistance or intolerance;
  • Subjects must be failing to achieve adequate virologic suppression on their current regimen and have -1 RNA ≥ 1000 copies/ml, at screening.
  • Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay.

Exclusion criteria

Exclusion Criteria:

  • Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials
  • Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    1

    Drug: Maraviroc

Interventions

  • Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AEs: any untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was congenital anomaly. Grade 3: Events that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4: Events which were unacceptable and intolerable or which were irreversible or caused participant to be in imminent danger of death.

    Time frame: Baseline to 30 days post-week 96 or early termination (ET)

  2. Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities

    Grade 3 or severe events included those that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 or very severe events included those that were unacceptable and intolerable or which were irreversible or caused the participant to be in imminent danger of death.

    Time frame: Baseline to 30 days post-week 96 or ET

  3. Number of Participants With Treatment Emergent Malignancies

    Time frame: Baseline to 30 days post-week 96 or ET

  4. Number of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections

    Number of participants with AIDS-related infections based on investigator classification guided by a predefined list of clinical Category C AEs per Center for Disease Control (CDC) HIV Classification System.

    Time frame: Baseline to 30 days post-week 96 or ET

  5. Number of Participants With Laboratory Test Abnormalities

    Pre-defined criteria based on upper limit normal (ULN) and lower limit normal (LLN) were established for each laboratory test to define the values that would be identified as laboratory test abnormality.

    Time frame: Baseline to 30 days post-week 96 or ET

Secondary outcomes

  1. Percentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA)

    Time frame: Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or end of treatment (EOT)

  2. Percentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA

    Time frame: Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  3. Percentage of Participants Achieving HIV-1 RNA Below Limit of Quantification

    Below limit of quantification was defined as less than 400 copies/milliliter (mL)

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  4. Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  5. Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  6. Change From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  7. Change From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  8. Number of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status

    Virus tropism was done by the Monogram Biosciences Trofile assay.

    Time frame: Time of virologic failure (VF) and Week 96 or EOT

Other outcomes

  1. Change From Baseline in Human Immunodeficiency Virus (HIV) -1 Viral Load (Ribonucleic Acid [RNA]) at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT

    Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log 10 copies per milliliter \[log10 copies/ml\]).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT

  2. Time to Virologic Failure (VF)

    Virologic failure was defined as failing to achieve a reduction in HIV-1 RNA of at least 0.5 log10 copies/ml from baseline by the second viral load determination; or experiencing at least 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline more than 0.5 log10 copies/ml; or experiencing an HIV-1 RNA more than 1000 copies/ml after having achieved an HIV-1 RNA below level of quantification.

    Time frame: Baseline to Week 96 or EOT

  3. Number of Participants With Genotype Resistance

    Evolution in resistance to OBT was shown by emergence of new primary or secondary resistance mutations to nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI).

    Time frame: Baseline through Week 96

07

Results

Posted Aug 8, 2011

Participant flow

Participant flow — Overall Study
MilestoneMaraviroc
Started209
Treated206
Completed125
Not completed84
Withdrew: Death7
Withdrew: Lack of efficacy47
Withdrew: Lost to follow-up7
Withdrew: Withdrawal by subject6
Withdrew: Other9
Withdrew: Adverse event5
Withdrew: Randomized, not treated3

Outcome measures

PrimaryNumber of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)

AEs: any untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was congenital anomaly. Grade 3: Events that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4: Events which were unacceptable and intolerable or which were irreversible or caused participant to be in imminent danger of death.

Time frame:
Baseline to 30 days post-week 96 or early termination (ET)
Reported as:
Number · Participants
Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsMaraviroc
Grade 3 AEs40
Grade 4 AEs9
SAEs34
PrimaryNumber of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities

Grade 3 or severe events included those that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 or very severe events included those that were unacceptable and intolerable or which were irreversible or caused the participant to be in imminent danger of death.

Time frame:
Baseline to 30 days post-week 96 or ET
Reported as:
Number · Participants
Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities
ParticipantsMaraviroc
Grade 3: Alanine aminotransferase (ALT)0
Grade 3: Aspartate aminotransferase (AST)4
Grade 3: Absolute neutrophil count (ANC)7
Grade 3: Alkaline phosphatase1
Grade 3: Gamma-glutamyl transpeptidase (GGT)15
Grade 3: Hyperbilirubinemia17
Grade 3: Hyperuricemia3
Grade 3: Lipase (n= 101)8
Grade 3: Platelets3
Grade 3: Potassium (Hyperkalemia)0
Grade 3: Serum amylase12
Grade 4: Alanine aminotransferase (ALT)1
Grade 4: Aspartate aminotransferase (AST)0
Grade 4: Absolute neutrophil count (ANC)4
Grade 4: Alkaline phosphatase0
Grade 4: Gamma-glutamyl transpeptidase (GGT)8
Grade 4: Hyperbilirubinemia6
Grade 4: Hyperuricemia1
Grade 4: Lipase (n= 101)2
Grade 4: Platelets0
Grade 4: Potassium (Hyperkalemia)2
Grade 4: Serum amylase1
PrimaryNumber of Participants With Treatment Emergent Malignancies
Time frame:
Baseline to 30 days post-week 96 or ET
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Malignancies
ParticipantsMaraviroc
Carcinoma in situ1
Hodgkin's disease1
Intestinal T-cell lymphoma1
Neoplasm of appendix1
PrimaryNumber of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections

Number of participants with AIDS-related infections based on investigator classification guided by a predefined list of clinical Category C AEs per Center for Disease Control (CDC) HIV Classification System.

Time frame:
Baseline to 30 days post-week 96 or ET
Reported as:
Number · Participants
Number of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections
ParticipantsMaraviroc
Cerebral toxoplasmosis2
Disseminated cryptococcosis1
Oesophageal candidiasis3
Pneumocystis jiroveci pneumonia3
Leukoencephalopathy1
PrimaryNumber of Participants With Laboratory Test Abnormalities

Pre-defined criteria based on upper limit normal (ULN) and lower limit normal (LLN) were established for each laboratory test to define the values that would be identified as laboratory test abnormality.

Time frame:
Baseline to 30 days post-week 96 or ET
Reported as:
Number · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsMaraviroc
Hematocrit (<0.8*LLN)13
Red blood cell count (<0.8*LLN)35
White blood cell count (<0.6*LLN)7
White blood cell count (>1.5*ULN)4
Absolute lymphocytes (<0.8*LLN)12
Absolute lymphocytes (>1.2*ULN)60
Percent lymphocytes (<0.8*LLN) (n= 1)0
Percent lymphocytes (>1.2*ULN) (n= 1)1
Percent neutrophils (<0.8*LLN) (n= 1)1
Percent neutrophils (>1.2*ULN) (n= 1)0
Absolute basophils (>1.2*ULN)10
Percent basophils (>1.2*ULN) (n= 1)0
Absolute eosinophils (>1.2*ULN)32
Percent eosinophils (>1.2*ULN) (n= 1)0
Absolute monocytes (>1.2*ULN)25
Percent monocytes (>1.2*ULN) (n= 1)0
Direct Bilirubin (>1.5*ULN)67
Indirect bilirubin (>1.5*ULN)25
Lactose dehydrogenase (LDH) (>3.0*ULN)1
Total protein (<0.8*LLN)1
Total protein (>1.2*ULN)19
Albumin (<0.8*LLN)3
Albumin (>1.2*ULN)0
Blood urea nitrogen (BUN) (>1.3*ULN)7
Cholesterol (>1.3*ULN)26
High density lipoprotein cholesterol (<0.8*LLN)115
Low density lipoprotein cholesterol (>1.2*ULN)101
Triglycerides (>1.3*ULN)145
Calcium (<0.9*LLN)6
Calcium (>1.1*ULN)0
Creatine kinase (CK) (>2.0*ULN)50
SecondaryPercentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA)
Time frame:
Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or end of treatment (EOT)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA)
Percentage of participantsMaraviroc
Week 4 (n= 202)78.7
Week 8 (n= 196)78.6
Week 12 (n= 190)80.5
Week 24 (n= 185)79.5
Week 36 (n= 171)83.6
Week 48 (n= 158)82.3
Week 60 (n= 141)84.4
Week 72 (n= 137)81.0
Week 84 (n= 125)82.4
Week 96 or EOT (n= 109)89.9
LOCF (n= 206)76.2
SecondaryPercentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA
Time frame:
Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA
Percentage of participantsMaraviroc
Week 4 (n= 202)67.8
Week 8 (n= 196)68.9
Week 12 (n= 190)71.1
Week 24 (n= 185)68.6
Week 36 (n= 171)69.0
Week 48 (n= 158)70.3
Week 60 (n= 141)70.2
Week 72 (n= 137)64.2
Week 84 (n= 125)71.2
Week 96 or EOT (n= 109)72.5
LOCF (n= 206)61.2
SecondaryPercentage of Participants Achieving HIV-1 RNA Below Limit of Quantification

Below limit of quantification was defined as less than 400 copies/milliliter (mL)

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HIV-1 RNA Below Limit of Quantification
Percentage of participantsMaraviroc
Baseline2.4
Week 4 (n= 202)29.7
Week 8 (n= 196)43.9
Week 12 (n= 190)42.6
Week 24 (n= 185)41.1
Week 36 (n= 171)47.4
Week 48 (n= 158)41.1
Week 60 (n= 141)36.2
Week 72 (n= 137)24.8
Week 84 (n= 125)23.2
Week 96 or EOT (n= 109)33.9
LOCF (n= 206)26.7
SecondaryChange From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Mean · cells per microliter (cells/µL)
Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
cells per microliter (cells/µL)Maraviroc
Baseline215.6 ± 179.9
Change at Week 4 (n= 190)93.5 ± 96.7
Change at Week 8 (n= 190)110.0 ± 95.2
Change at Week 12 (n= 186)132.1 ± 164.1
Change at Week 24 (n= 184)137.3 ± 115.0
Change at Week 36 (n= 165)157.8 ± 128.4
Change at Week 48 (n= 154)172.2 ± 124.0
Change at Week 60 (n= 134)187.2 ± 140.4
Change at Week 72 (n= 129)199.8 ± 161.0
Change at Week 84 (n= 124)198.2 ± 177.3
Change at Week 96 or EOT (n= 107)225.2 ± 175.3
Change at LOCF (n= 201)174.1 ± 168.5
SecondaryChange From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Mean · cells/µL
Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
cells/µLMaraviroc
Baseline1016.4 ± 676.3
Change at Week 4 (n= 190)387.3 ± 597.0
Change at Week 8 (n= 190)518.3 ± 666.4
Change at Week 12 (n= 186)507.2 ± 685.6
Change at Week 24 (n= 185)358.1 ± 577.2
Change at Week 36 (n= 165)352.3 ± 545.3
Change at Week 48 (n= 155)348.6 ± 591.0
Change at Week 60 (n= 135)349.1 ± 566.7
Change at Week 72 (n= 130)272.4 ± 594.8
Change at Week 84 (n= 124)246.7 ± 567.3
Change at Week 96 or EOT (n= 107)214.5 ± 593.2
Change at LOCF (n= 201)223.0 ± 562.0
SecondaryChange From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Mean · Percent CD4
Change From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Percent CD4Maraviroc
Baseline12.2 ± 7.5
Change at Week 4 (n= 190)1.8 ± 3.4
Change at Week 8 (n= 190)1.3 ± 3.2
Change at Week 12 (n= 186)2.1 ± 4.4
Change at Week 24 (n= 184)2.9 ± 3.7
Change at Week 36 (n= 165)3.6 ± 3.9
Change at Week 48 (n= 154)4.3 ± 4.1
Change at Week 60 (n= 134)4.5 ± 4.5
Change at Week 72 (n= 129)5.2 ± 4.3
Change at Week 84 (n= 124)5.3 ± 5.2
Change at Week 96 or EOT (n= 107)6.6 ± 5.1
Change at LOCF (n= 201)4.9 ± 5.3
SecondaryChange From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Mean · Percent CD8
Change From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Percent CD8Maraviroc
Baseline59.8 ± 13.1
Change at Week 4 (n= 190)0.4 ± 6.1
Change at Week 8 (n= 190)0.9 ± 7.3
Change at Week 12 (n= 186)-0.1 ± 8.2
Change at Week 24 (n= 185)-2.5 ± 8.3
Change at Week 36 (n= 165)-3.6 ± 8.6
Change at Week 48 (n= 155)-4.3 ± 9.9
Change at Week 60 (n= 135)-4.7 ± 10.4
Change at Week 72 (n= 130)-6.1 ± 10.9
Change at Week 84 (n= 124)-6.8 ± 10.3
Change at Week 96 or EOT (n= 107)-7.7 ± 10.7
Change at LOCF (n= 201)-5.4 ± 10.6
SecondaryNumber of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status

Virus tropism was done by the Monogram Biosciences Trofile assay.

Time frame:
Time of virologic failure (VF) and Week 96 or EOT
Reported as:
Number · Participants
Number of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status
ParticipantsMaraviroc
VF X4 (n= 134)7
EOT X4 (n= 146)8
Other pre-specifiedChange From Baseline in Human Immunodeficiency Virus (HIV) -1 Viral Load (Ribonucleic Acid [RNA]) at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT

Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log 10 copies per milliliter \[log10 copies/ml\]).

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Reported as:
Mean · log 10 copies/ml
Change From Baseline in Human Immunodeficiency Virus (HIV) -1 Viral Load (Ribonucleic Acid [RNA]) at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
log 10 copies/mlMaraviroc
Baseline4.8 ± 0.9
Change at week 4 (n= 202)-1.5 ± 1.0
Change at week 8 (n= 196)-1.5 ± 1.1
Change at week 12 (n= 190)-1.6 ± 1.1
Change at week 24 (n= 185)-1.6 ± 1.1
Change at week 36 (n= 171)-1.6 ± 1.0
Change at week 48 (n= 158)-1.6 ± 1.0
Change at week 60 (n= 141)-1.6 ± 1.1
Change at week 72 (n= 137)-1.4 ± 1.1
Change at week 84 (n= 125)-1.5 ± 1.1
Change at week 96 or EOT (n= 109)-1.7 ± 1.0
Change at LOCF (n= 206)-1.4 ± 1.1
Other pre-specifiedTime to Virologic Failure (VF)

Virologic failure was defined as failing to achieve a reduction in HIV-1 RNA of at least 0.5 log10 copies/ml from baseline by the second viral load determination; or experiencing at least 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline more than 0.5 log10 copies/ml; or experiencing an HIV-1 RNA more than 1000 copies/ml after having achieved an HIV-1 RNA below level of quantification.

Time frame:
Baseline to Week 96 or EOT
Reported as:
Median · Days
Time to Virologic Failure (VF)
DaysMaraviroc
Time to Virologic Failure (VF)255.0 (172.0 to 336.0)
Other pre-specifiedNumber of Participants With Genotype Resistance

Evolution in resistance to OBT was shown by emergence of new primary or secondary resistance mutations to nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI).

Time frame:
Baseline through Week 96
Reported as:
Number · Participants
Number of Participants With Genotype Resistance
ParticipantsMaraviroc
VF: NRTI0
VF: NNRTI0
VF: PI16
VF: NRTI and NNRTI0
VF: NRTI and PI32
VF: NNRTI and PI7
VF: NRTI and NNRTI and PI64
VF: no NRTI, no NNRTI and no PI0
VF: no test result data48

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc—34/206 (16.5%)185/206 (89.8%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventMaraviroc
SepsisInfections and infestations4/206
PyrexiaGeneral disorders3/206
PneumoniaInfections and infestations3/206
ConvulsionNervous system disorders3/206
Abdominal painGastrointestinal disorders2/206
DiarrhoeaGastrointestinal disorders2/206
VomitingGastrointestinal disorders2/206
DyspnoeaRespiratory, thoracic and mediastinal disorders2/206
AnaemiaBlood and lymphatic system disorders1/206
Febrile neutropeniaBlood and lymphatic system disorders1/206
Most frequent other events
Showing 10 of 355
Most frequent other events
EventMaraviroc
DiarrhoeaGastrointestinal disorders33/206
NasopharyngitisInfections and infestations32/206
HeadacheNervous system disorders22/206
Subcutaneous noduleSkin and subcutaneous tissue disorders22/206
SinusitisInfections and infestations18/206
NauseaGastrointestinal disorders17/206
Upper respiratory tract infectionInfections and infestations17/206
HypertriglyceridaemiaMetabolism and nutrition disorders17/206
RashSkin and subcutaneous tissue disorders15/206
VomitingGastrointestinal disorders14/206

Baseline characteristics

Age Continuous
Age Continuous(Years)Maraviroc
Mean43.2 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Maraviroc
Female61
Male145
08

Study locations

16 sites
  • Pfizer Investigational Site
    Salvador, BA 40110-160, Brazil
  • Pfizer Investigational Site
    Brasilia, DF 70351-580, Brazil
  • Pfizer Investigational Site
    Belo Horizonte, MG 30130-100, Brazil
  • Pfizer Investigational Site
    Curitiba, PR 80240-280, Brazil
  • Pfizer Investigational Site
    Nova Iguaçu, RJ 26030-380, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS 90110-270, Brazil
  • Pfizer Investigational Site
    Florianopolis, SC 88025-301, Brazil
  • Pfizer Investigational Site
    Campinas, SP 13059-900, Brazil
  • Pfizer Investigational Site
    Campinas, SP 13083-887, Brazil
  • Pfizer Investigational Site
    Ribeirao Preto, SP 14048900, Brazil
  • Pfizer Investigational Site
    Santo Andre, SP 09060-650, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01246-900, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01307-001, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04040-002, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04121-000, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04231-030, Brazil
09

References and documents

Publications

  • Furtado J, Madruga JV, Bicudo EL, da Eira M, Lopes MI, Netto EM, Santini-Oliveira M, Leite OH, Machado AA, Tupinambas U, de Andrade Neto JL, Lima MP, Pedro Rde J, Miranda AF, Lewi DS, Santos BR, Portsmouth S, Wajsbrot DB, Cassoli LM. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study. AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25. PubMed 23731330 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Aug 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2007
First posted
May 24, 2007
Start
Jul 2007
Primary completionActual
Aug 2010
CompletionActual
Sep 2010
Results first posted
Aug 8, 2011
Last update
Sep 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00478231
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
May 24, 2007
Start date
Jul 2007
Primary completion
Aug 2010
Completion
Sep 2010
Results posted
Aug 8, 2011
Last update
Sep 9, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion